When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
Adamas Pharmaceuticals (ADMS) publicized their INROADS study in multiple sclerosis “MS” patients with walking impairment met its primary endpoint but missed on its secondary endpoints. The results exhibited that patients taking 274 mg of GOCOVRI had a statistically significant 21.1% improvement matched to 11.3% placebo in the Timed 25 ft. Walk Test. Although GOCOVRI was able to hit its primary endpoint, the company was disappointed in the results and is now attempting to decide what they are going to do with GOCOVRI in MS-Walking. In response to the company press release, the